Dark Pharma · DP-042
The Internal Data Showed The Weight Gain. The Marketing Said Something Else.
AstraZeneca faced numerous lawsuits alleging they concealed internal data linking Seroquel to significant weight gain and diabetes risk. Despite this, the marketing strategy portrayed the drug as having a favorable metabolic profile, leading to severe legal and financial repercussions.
Case Assets
The Case Debrief is free to view. Full Case Study, Teaching Notes, Slide Deck, Discussion Guide, and Assessment are available with a Premium subscription.
Brief the Board
PREMIUM
🔒 Unlock
Learn the Case
FREE — included
Study the Case
PREMIUM
🔒 Unlock
Teach the Case
PREMIUM
🔒 Unlock
Present the Case
PREMIUM
🔒 Unlock
Run a Team Discussion
PREMIUM
🔒 Unlock
Test Your Judgement
PREMIUM
🔒 Unlock
Watch the Full Episode
The complete cinematic audio documentary — Dark Pharma
Unlock the Full Case Library
Get every Case Study, Slide Deck, Teaching Notes, Discussion Guide, and Assessment — across a growing library of business cases.
View Pricing →Related Cases
Cases that share a governance or behavioural model with this one.
Dark Law
DL-034
HE BUILT A LICENSING WORKAROUND INTO THE PRODUCT. THE REGULATOR CALLED...
Shared: Compliance Framework, Risk Management Committee, Whistleblower Protection
Dark Pharma
DP-041
The Key Trial Site Enrolled Patients Who Didn't Exist. The Drug Was Ap...
Shared: Whistleblower Protection, Transparency Protocol
Empire Builders
EB-045
SHE SENT SEVENTEEN ENVELOPES TO BARON VON DINCKLAGE. THE PIERRE FAMILY...
Shared: Compliance Framework, Whistleblower Protection
Dark Pharma
DP-031
HE PAID THE DOCTORS $3,200 PER DINNER. THE DINNERS LASTED NINETEEN MIN...
Shared: Compliance Framework, Transparency Protocol